New Triple-Threat treatment tested for tough skin cancers
NCT ID NCT06784648
Summary
This trial is testing a new antibody drug, called BI-1607, to see if it makes two existing melanoma treatments (ipilimumab and pembrolizumab) work better. It will involve about 35 adults whose advanced melanoma has continued to grow despite standard treatment. The main goals are to find a safe dose for the new combination and to see if it helps shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitatsmedizin Berlin
Berlin, Germany
-
Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
Sarah Cannon Research Institute UK
London, Greater London, W1G 6AD, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
University Hospital 12 de Octubre
Madrid, Spain
-
University Hospital Essen
Essen, Germany
-
University Hospital Heidelberg
Heidelberg, Germany
-
University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg and Clinical Cooperation Unit Dermato-Oncology(G300) German Cancer Research Center(DKFZ)
Mannheim, Germany
-
Velindre Cancer Centre
Cardiff, Wales, CF14 2TL, United Kingdom
Conditions
Explore the condition pages connected to this study.